Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

08-04-2022 | Positron Emission Tomography | Review Article

Advances in aptamer-based nuclear imaging

Authors: Wenyu Song, Yangmeihui Song, Qian Li, Chunhai Fan, Xiaoli Lan, Dawei Jiang

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2022

Abstract

Aptamers are short oligonucleotides that bind to specific target molecules. They have been extensively explored in biomedical applications, including biosensing, medical imaging, and disease treatment. Their adjustable affinity for specific biomarkers stimulates more translational efforts, such as nuclear imaging of tumors in preclinical and clinical settings. In this review, we present recent advances of aptamer-based nuclear imaging and compare aptamer tracers with other biogenic probes in forms of peptides, nanobodies, monoclonal antibodies, and antibody fragments. Fundamental properties of aptamer-based radiotracers are highlighted and potential directions to improve aptamer’s imaging performance are discussed. Despite many translational obstacles to overcome, we envision aptamers to be a versatile tool for cancer nuclear imaging in the near future.

Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR, et al. PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE. 2019;14(1): e0211047. https://doi.org/10.1371/journal.pone.0211047.CrossRefPubMedPubMedCentral

Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505–10. https://doi.org/10.1126/science.2200121.CrossRefPubMed

Stoltenburg R, Reinemann C, Strehlitz B. SELEX–a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng. 2007;24(4):381–403. https://doi.org/10.1016/j.bioeng.2007.06.001.CrossRefPubMed

Odeh F, Nsairat H, Alshaer W, Ismail MA, Esawi E, Qaqish B et al. Aptamers chemistry: chemical modifications and conjugation strategies. Molecules. 2019;25(1). https://doi.org/10.3390/molecules25010003.

Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem. 2011;18(27):4206–14. https://doi.org/10.2174/092986711797189600.CrossRefPubMedPubMedCentral

Kim JH, Marton J, Ametamey SM, Cumming P. A review of molecular imaging of glutamate receptors. Molecules. 2020;25(20). https://doi.org/10.3390/molecules25204749.

Zhang X, Ding B, Qu C, Li H, Sun Y, Gai Y, et al. A thiopyrylium salt for PET/NIR-II tumor imaging and image-guided surgery. Mol Oncol. 2020;14(5):1089–100. https://doi.org/10.1002/1878-0261.12674.CrossRefPubMedPubMedCentral

Farzin L, Shamsipur M, Moassesi ME, Sheibani S. Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: a new class of targeted radiopharmaceuticals. Bioorg Med Chem. 2019;27(12):2282–91. https://doi.org/10.1016/j.bmc.2018.11.031.CrossRefPubMed

Son H, Jang K, Lee H, Kim SE, Kang KW, Lee H. Use of molecular imaging in clinical drug development: a systematic review. Nucl Med Mol Imaging. 2019;53(3):208–15. https://doi.org/10.1007/s13139-019-00593-y.CrossRefPubMedPubMedCentral

10.

Han J, Gao L, Wang J, Wang J. Application and development of aptamer in cancer: from clinical diagnosis to cancer therapy. J Cancer. 2020;11(23):6902–15. https://doi.org/10.7150/jca.49532.CrossRefPubMedPubMedCentral

11.

Bakhtiari H, Palizban AA, Khanahmad H, Mofid MR. Aptamer-based approaches for in vitro molecular detection of cancer. Res Pharm Sci. 2020;15(2):107–22. https://doi.org/10.4103/1735-5362.283811.CrossRefPubMedPubMedCentral

12.

Filippi L, Bagni O, Nervi C. Aptamer-based technology for radionuclide targeted imaging and therapy: a promising weapon against cancer. Expert Rev Med Devices. 2020;17(8):751–8. https://doi.org/10.1080/17434440.2020.1796633.CrossRefPubMed

13.

Ruiz Ciancio D, Vargas MR, Thiel WH, Bruno MA, Giangrande PH, Mestre MB. Aptamers as diagnostic tools in cancer. Pharmaceuticals (Basel). 2018;11(3). https://doi.org/10.3390/ph11030086.

14.

Liu C, Liu T, Zhang N, Liu Y, Li N, Du P, et al. (68)Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2018;45(11):1852–61. https://doi.org/10.1007/s00259-018-4037-9.CrossRefPubMed

15.

Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med. 2019;60(Suppl 2):13S-S19. https://doi.org/10.2967/jnumed.118.220566.CrossRefPubMed

16.

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.CrossRefPubMed

17.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

18.

Yanahan D, Weinberg RA, Hallm-Yang CW, Budak H. Exploiting stokes and anti-stokes type emission profiles of aptamer-functionalized luminescent nanoprobes for multiplex sensing applications. ChemistrySelect. 2018;3(21):5814–23. https://doi.org/10.1002/slct.201801008.CrossRef

19.

Zhang H, Zhou L, Zhu Z, Yang C. Recent progress in aptamer-based functional probes for bioanalysis and biomedicine. Chemistry (Easton). 2016;22(29):9886–900. https://doi.org/10.1002/chem.201503543.CrossRef

20.

Liu Y, Yang G, Li T, Deng Y, Chen Z, He N. Selection of a DNA aptamer for the development of fluorescent aptasensor for carbaryl detection. Chin Chem Lett. 2021;32(6):1957–62. https://doi.org/10.1016/j.cclet.2021.01.016.CrossRef

21.

Yang G, Zhu C, Zhao L, Li L, Huang Y, Zhang Y, et al. Pressure controllable aptamers picking strategy by targets competition. Chin Chem Lett. 2021;32(1):218–20. https://doi.org/10.1016/j.cclet.2020.10.018.CrossRef

22.

Borghei YS, Hosseini M, Dadmehr M, Hosseinkhani S, Ganjali MR, Sheikhnejad R. Visual detection of cancer cells by colorimetric aptasensor based on aggregation of gold nanoparticles induced by DNA hybridization. Anal Chim Acta. 2016;904:92–7. https://doi.org/10.1016/j.aca.2015.11.026.CrossRefPubMed

23.

Leitner M, Poturnayova A, Lamprecht C, Weich S, Snejdarkova M, Karpisova I, et al. Characterization of the specific interaction between the DNA aptamer sgc8c and protein tyrosine kinase-7 receptors at the surface of T-cells by biosensing AFM. Anal Bioanal Chem. 2017;409(11):2767–76. https://doi.org/10.1007/s00216-017-0238-5.CrossRefPubMedPubMedCentral

24.

Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A. 2006;103(32):11838–43. https://doi.org/10.1073/pnas.0602615103.CrossRefPubMedPubMedCentral

25.

Zheng Y, Zhao Y, Di Y, Xiu C, He L, Liao S, et al. DNA aptamers from whole-serum SELEX as new diagnostic agents against gastric cancer. RSC Adv. 2019;9(2):950–7. https://doi.org/10.1039/c8ra08642g.CrossRefPubMedPubMedCentral

26.

Bayrac AT, Sefah K, Parekh P, Bayrac C, Gulbakan B, Oktem HA, et al. In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem Neurosci. 2011;2(3):175–81. https://doi.org/10.1021/cn100114k.CrossRefPubMedPubMedCentral

27.

Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci. 2011;102(5):991–8. https://doi.org/10.1111/j.1349-7006.2011.01897.x.CrossRefPubMed

28.

Khoshfetrat SM, Mehrgardi MA. Amplified detection of leukemia cancer cells using an aptamer-conjugated gold-coated magnetic nanoparticles on a nitrogen-doped graphene modified electrode. Bioelectrochemistry. 2017;114:24–32. https://doi.org/10.1016/j.bioelechem.2016.12.001.CrossRefPubMed

29.

Li F, Wang Q, Zhang H, Deng T, Feng P, Hu B, et al. Characterization of a DNA aptamer for ovarian cancer clinical tissue recognition and in vivo imaging. Cell Physiol Biochem. 2018;51(6):2564–74. https://doi.org/10.1159/000495925.CrossRefPubMed

30.

An Y, Hu Y, Li X, Li Z, Duan J, Yang XD. Selection of a novel DNA aptamer against OFA/iLRP for targeted delivery of doxorubicin to AML cells. Sci Rep. 2019;9(1):7343. https://doi.org/10.1038/s41598-019-43910-3.CrossRefPubMedPubMedCentral

31.

Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci. 2003;100(26):15416. https://doi.org/10.1073/pnas.2136683100.CrossRefPubMedPubMedCentral

32.

Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol. 1997;4(11):809–16. https://doi.org/10.1016/s1074-5521(97)90114-9.CrossRefPubMed

33.

Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, et al. Tumor targeting by an aptamer. J Nucl Med. 2006;47(4):668–78.PubMed

34.

Wang L, Jacobson O, Avdic D, Rotstein BH, Weiss ID, Collier L, et al. Ortho-stabilized (18) F-azido click agents and their application in PET imaging with single-stranded DNA aptamers. Angew Chem Int Ed Engl. 2015;54(43):12777–81. https://doi.org/10.1002/anie.201505927.CrossRefPubMedPubMedCentral

35.

Li J, Zheng H, Bates PJ, Malik T, Li XF, Trent JO, et al. Aptamer imaging with Cu-64 labeled AS1411: preliminary assessment in lung cancer. Nucl Med Biol. 2014;41(2):179–85. https://doi.org/10.1016/j.nucmedbio.2013.10.008.CrossRefPubMed

36.

Wu X, Liang H, Tan Y, Yuan C, Li S, Li X, et al. Cell-SELEX aptamer for highly specific radionuclide molecular imaging of glioblastoma in vivo. PLoS ONE. 2014;9(6): e90752. https://doi.org/10.1371/journal.pone.0090752.CrossRefPubMedPubMedCentral

37.

Jacobson O, Yan X, Niu G, Weiss ID, Ma Y, Szajek LP, et al. PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer. J Nucl Med. 2015;56(4):616–21. https://doi.org/10.2967/jnumed.114.149484.CrossRefPubMed

38.

Park JY, Lee TS, Song IH, Cho YL, Chae JR, Yun M, et al. Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging. Biomaterials. 2016;100:143–51. https://doi.org/10.1016/j.biomaterials.2016.05.035.CrossRefPubMed

39.

de Sousa Lacerda CM, Ferreira IM, Dos Santos SR, de Barros AL, Fernandes SO, Cardoso VN, et al. (1–>3)-beta-D-glucan aptamers labeled with technetium-99m: Biodistribution and imaging in experimental models of bacterial and fungal infection. Nucl Med Biol. 2017;46:19–24. https://doi.org/10.1016/j.nucmedbio.2016.11.008.CrossRefPubMed

40.

Ferreira IM, de Sousa Lacerda CM, Dos Santos SR, de Barros ALB, Fernandes SO, Cardoso VN, et al. Detection of bacterial infection by a technetium-99m-labeled peptidoglycan aptamer. Biomed Pharmacother. 2017;93:931–8. https://doi.org/10.1016/j.biopha.2017.07.017.CrossRefPubMed

41.

Santos SRD, de Sousa Lacerda CM, Ferreira IM, de Barros ALB, Fernandes SO, Cardoso VN, et al. Scintigraphic imaging of Staphylococcus aureus infection using (99m)Tc radiolabeled aptamers. Appl Radiat Isot. 2017;128:22–7. https://doi.org/10.1016/j.apradiso.2017.06.043.CrossRefPubMed

42.

Fletcher NL, Houston ZH, Simpson JD, Veedu RN, Thurecht KJ. Designed multifunctional polymeric nanomedicines: long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials. Chem Commun (Camb). 2018;54(82):11538–41. https://doi.org/10.1039/c8cc05831h.CrossRef

43.

Cheng S, Jacobson O, Zhu G, Chen Z, Liang SH, Tian R, et al. PET imaging of EGFR expression using an (18)F-labeled RNA aptamer. Eur J Nucl Med Mol Imaging. 2019;46(4):948–56. https://doi.org/10.1007/s00259-018-4105-1.CrossRefPubMed

44.

Tajrishi MM, Tuteja R, Tuteja N. Nucleolin: the most abundant multifunctional phosphoprotein of nucleolus. Commun Integr Biol. 2011;4(3):267–75. https://doi.org/10.4161/cib.4.3.14884.CrossRefPubMedPubMedCentral

45.

Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 2008;68(7):2358–65. https://doi.org/10.1158/0008-5472.CAN-07-5723.CrossRefPubMed

46.

Palmieri D, Richmond T, Piovan C, Sheetz T, Zanesi N, Troise F, et al. Human anti-nucleolin recombinant immunoagent for cancer therapy. Proc Natl Acad Sci U S A. 2015;112(30):9418–23. https://doi.org/10.1073/pnas.1507087112.CrossRefPubMedPubMedCentral

47.

Girvan AC, Teng Y, Casson LK, Thomas SD, Juliger S, Ball MW, et al. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol Cancer Ther. 2006;5(7):1790–9. https://doi.org/10.1158/1535-7163.MCT-05-0361.CrossRefPubMed

48.

Hwang DW, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med. 2010;51(1):98–105. https://doi.org/10.2967/jnumed.109.069880.CrossRefPubMed

49.

Park JY, Cho YL, Chae JR, Moon SH, Cho WG, Choi YJ, et al. Gemcitabine-incorporated G-quadruplex aptamer for targeted drug delivery into pancreas cancer. Mol Ther Nucleic Acids. 2018;12:543–53. https://doi.org/10.1016/j.omtn.2018.06.003.CrossRefPubMedPubMedCentral

50.

Yang S, Li H, Xu L, Deng Z, Han W, Liu Y, et al. Oligonucleotide aptamer-mediated precision therapy of hematological malignancies. Mol Ther Nucleic Acids. 2018;13:164–75. https://doi.org/10.1016/j.omtn.2018.08.023.CrossRefPubMedPubMedCentral

51.

Abatemarco J, Sarhan MF, Wagner JM, Lin JL, Liu L, Hassouneh W, et al. RNA-aptamers-in-droplets (RAPID) high-throughput screening for secretory phenotypes. Nat Commun. 2017;8(1):332. https://doi.org/10.1038/s41467-017-00425-7.CrossRefPubMedPubMedCentral

52.

Bhojani MS, Ranga R, Luker GD, Rehemtulla A, Ross BD, Van Dort ME. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS ONE. 2011;6(7): e22418. https://doi.org/10.1371/journal.pone.0022418.CrossRefPubMedPubMedCentral

53.

Tong X, Ga L, Ai J, Wang Y. Progress in cancer drug delivery based on AS1411 oriented nanomaterials. J Nanobiotechnology. 2022;20(1):57. https://doi.org/10.1186/s12951-022-01240-z.CrossRefPubMedPubMedCentral

54.

Lam PY, Hillyar CR, Able S, Vallis KA. Synthesis and evaluation of an (18) F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cells. J Labelled Comp Radiopharm. 2016;59(12):492–9. https://doi.org/10.1002/jlcr.3439.CrossRefPubMedPubMedCentral

55.

Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39. https://doi.org/10.1002/jcb.10661.CrossRefPubMed

56.

Dassie JP, Hernandez LI, Thomas GS, Long ME, Rockey WM, Howell CA, et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. Mol Ther. 2014;22(11):1910–22. https://doi.org/10.1038/mt.2014.117.CrossRefPubMedPubMedCentral

57.

Yang T, Jiao J, Lv Y, Zhou Q, Cao S, Jiang S, et al. Preparation and preclinical study of 99m technetium labeled PSMA aptamer for prostate cancer. JOURNAL OF SUN YAT⁃SEN UNIVERSITY(MEDICAL SCIENCES). 2017;38(006):848–53.

58.

Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97. https://doi.org/10.1021/bc200279b.CrossRefPubMed

59.

Bois F, Noirot C, Dietemann S, Mainta IC, Zilli T, Garibotto V, et al. [(68)Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. Am J Nucl Med Mol Imaging. 2020;10(6):349–74.PubMedPubMedCentral

60.

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51(8):1293–300. https://doi.org/10.2967/jnumed.110.076174.CrossRefPubMed

61.

Evazalipour M, D’Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, et al. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging. 2014;9(3):211–20. https://doi.org/10.1002/cmmi.1558.CrossRefPubMed

62.

Saule L, Radzina M, Liepa M, Roznere L, Kalnina M, Lioznovs A, et al. Diagnostic scope of (18)F-PSMA-1007 PET/CT: comparison with multiparametric MRI and bone scintigraphy for the assessment of early prostate cancer recurrence. Am J Nucl Med Mol Imaging. 2021;11(5):395–405.PubMedPubMedCentral

63.

Medina-Ornelas S, Garcia-Perez F, Estrada-Lobato E, Ochoa-Carrillo F. (68)Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience. Am J Nucl Med Mol Imaging. 2020;10(3):135–42.PubMedPubMedCentral

64.

Han S, Woo S, Kim YJ, Suh CH. Impact of 68Ga-PSMA PET on the Management of Patients with Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018;74(2):179–90. https://doi.org/10.1016/j.eururo.2018.03.030.CrossRefPubMed

65.

Hinkle GH, Burgers JK, Olsen JO, Williams BS, Lamatrice RA, Barth RF, et al. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. J Nucl Med. 1998;39(4):650–2.PubMed

66.

Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, et al. New prostate cancer targets for diagnosis, imaging, and therapy: focus on prostate-specific membrane antigen. Front Oncol. 2018;8:653. https://doi.org/10.3389/fonc.2018.00653.CrossRefPubMedPubMedCentral

67.

Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91. https://doi.org/10.1158/1078-0432.Ccr-13-0231.CrossRefPubMedPubMedCentral

68.

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O’Sullivan JM, et al. Advances in targeted alpha therapy for prostate cancer. Ann Oncol. 2019;30(11):1728–39. https://doi.org/10.1093/annonc/mdz270.CrossRefPubMedPubMedCentral

69.

Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125(15):2561–9. https://doi.org/10.1002/cncr.32072.CrossRefPubMed

70.

Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182. https://doi.org/10.3389/fonc.2020.01182.CrossRefPubMedPubMedCentral

71.

Wang Y, Fan Z, Shao L, Kong X, Hou X, Tian D, et al. Nanobody-derived nanobiotechnology tool kits for diverse biomedical and biotechnology applications. Int J Nanomedicine. 2016;11:3287–303. https://doi.org/10.2147/IJN.S107194.CrossRefPubMedPubMedCentral

72.

Zagzag D, Friedlander DR, Miller DC, Dosik J, Cangiarella J, Kostianovsky M, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res. 1995;55(4):907–14.PubMed

73.

Heuveling DA, de Bree R, Vugts DJ, Huisman MC, Giovannoni L, Hoekstra OS, et al. Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med. 2013;54(3):397–401. https://doi.org/10.2967/jnumed.112.111310.CrossRefPubMed

74.

Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemotherapy Research and Practice. 2012;2012: 743193. https://doi.org/10.1155/2012/743193.CrossRefPubMedPubMedCentral

75.

Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463–75. https://doi.org/10.1038/nrc2656.CrossRefPubMed

76.

Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K. Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using cell-SELEX. Iran J Basic Med Sci. 2015;18(6):576–86.PubMedPubMedCentral

77.

Jiang D, Im HJ, Sun H, Valdovinos HF, England CG, Ehlerding EB, et al. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017;44(8):1296–305. https://doi.org/10.1007/s00259-017-3663-y.CrossRefPubMedPubMedCentral

78.

Wei W, Jiang D, Rosenkrans ZT, Barnhart TE, Engle JW, Luo Q, et al. HER2-targeted multimodal imaging of anaplastic thyroid cancer. Am J Cancer Res. 2019;9(11):2413–27.PubMedPubMedCentral

79.

Gaykema SB, Schröder CP, Vitfell-Rasmussen J, Chua S, Oude Munnink TH, Brouwers AH, et al. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the HSP90 inhibitor NVP-AUY922 in metastatic breast cancer patients. Clin Cancer Res. 2014;20(15):3945–54. https://doi.org/10.1158/1078-0432.Ccr-14-0491.CrossRefPubMed

80.

Gaykema SB, Brouwers AH, Hovenga S, Lub-de Hooge MN, de Vries EG, Schröder CP. Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer. J Clin Oncol. 2012;30(6):e74–5. https://doi.org/10.1200/jco.2011.38.0204.CrossRefPubMed

81.

Lee HJ, Ehlerding EB, Jiang D, Barnhart TE, Cao T, Wei W, et al. Dual-labeled pertuzumab for multimodality image-guided ovarian tumor resection. Am J Cancer Res. 2019;9(7):1454–68.PubMedPubMedCentral

82.

Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I Study of 68Ga-HER2-nanobody for PET/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57(1):27–33. https://doi.org/10.2967/jnumed.115.162024.CrossRefPubMed

83.

Velikyan I, Schweighöfer P, Feldwisch J, Seemann J, Frejd FY, Lindman H, et al. Diagnostic HER2-binding radiopharmaceutical, [(68)Ga]Ga-ABY-025, for routine clinical use in breast cancer patients. Am J Nucl Med Mol Imaging. 2019;9(1):12–23.PubMedPubMedCentral

84.

Velikyan I, Wennborg A, Feldwisch J, Lindman H, Carlsson J, Sörensen J. Good manufacturing practice production of [(68)Ga]Ga-ABY-025 for HER2 specific breast cancer imaging. Am J Nucl Med Mol Imaging. 2016;6(2):135–53.PubMedPubMedCentral

85.

Jacobson O, Weiss ID, Wang L, Wang Z, Yang X, Dewhurst A, et al. 18F-labeled single-stranded DNA aptamer for pet imaging of protein tyrosine kinase-7 expression. J Nucl Med. 2015;56(11):1780–5. https://doi.org/10.2967/jnumed.115.160960.CrossRefPubMed

86.

Zhang X, Potty AS, Jackson GW, Stepanov V, Tang A, Liu Y, et al. Engineered 5S ribosomal RNAs displaying aptamers recognizing vascular endothelial growth factor and malachite green. J Mol Recognit. 2009;22(2):154–61. https://doi.org/10.1002/jmr.917.CrossRefPubMed

87.

Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: beyond discovery and development. Cell. 2019;176(6):1248–64. https://doi.org/10.1016/j.cell.2019.01.021.CrossRefPubMedPubMedCentral

88.

Roth DB, Prenner JL, Green SN, Yarian DL, Leff SR, Friedman ES, et al. Early clinical experience with pegaptanib sodium (Macugen) in age–related macular degeneration. Invest Ophthalmol Vis Sci. 2006;47(13):2149-.

89.

Qin ZX, Li QW, Liu GY, Luo CX, Xie GF, Zheng L, et al. Imaging targeted at tumor with (188)Re-labeled VEGF(189) exon 6-encoded peptide and effects of the transfecting truncated KDR gene in tumor-bearing nude mice. Nucl Med Biol. 2009;36(5):535–43. https://doi.org/10.1016/j.nucmedbio.2009.02.001.CrossRefPubMed

90.

Chen H, Ding X, Gao Y, Jiang X, Liu X, Chen Y, et al. Inhibition of angiogenesis by a novel neutralizing antibody targeting human VEGFR-3. MAbs. 2013;5(6):956–61. https://doi.org/10.4161/mabs.26239.CrossRefPubMedPubMedCentral

91.

Arjaans M, Schröder CP, Oosting SF, Dafni U, Kleibeuker JE, de Vries EGE. VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside. 2016;7(16). https://doi.org/10.18632/oncotarget.6918.

92.

Gu Y, Wang J, Li K, Zhang L, Ren H, Guo L, et al. Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemother Pharmacol. 2014;74(1):95–115. https://doi.org/10.1007/s00280-014-2471-3.CrossRefPubMed

93.

González-Ruíz A, Ferro-Flores G, Jiménez-Mancilla N, Escudero-Castellanos A, Ocampo-García B, Luna-Gutiérrez M, et al. In vitro and in vivo synergistic effect of radiotherapy and plasmonic photothermal therapy on the viability of cancer cells using 177Lu–Au-NLS-RGD-Aptamer nanoparticles under laser irradiation. J Radioanal Nucl Chem. 2018;318(3):1913–21. https://doi.org/10.1007/s10967-018-6266-6.CrossRef

94.

Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med. 2009;50(7):1116–23. https://doi.org/10.2967/jnumed.109.061820.CrossRefPubMed

95.

Li X, Zhang L, Guo X, Xie F, Shen C, Jun Y, et al. Self-assembled RNA nanocarrier-mediated chemotherapy combined with molecular targeting in the treatment of esophageal squamous cell carcinoma. J Nanobiotechnology. 2021;19(1):388. https://doi.org/10.1186/s12951-021-01135-5.CrossRefPubMedPubMedCentral

96.

Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020;12(7). https://doi.org/10.3390/pharmaceutics12070604.

97.

Tian L, Shao M, Gong Y, Chao Y, Wei T, Yang K, et al. Albumin-binding lipid-aptamer conjugates for cancer immunoimaging and immunotherapy. SCIENCE CHINA Chem. 2021. https://doi.org/10.1007/s11426-021-1168-4.CrossRef

98.

Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9(7):537–50. https://doi.org/10.1038/nrd3141.CrossRefPubMedPubMedCentral

99.

Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol. 2010;6(1):22–4. https://doi.org/10.1038/nchembio.277.CrossRefPubMed

100.

Xing S, Jiang D, Li F, Li J, Li Q, Huang Q, et al. Constructing higher-order DNA nanoarchitectures with highly purified DNA nanocages. ACS Appl Mater Interfaces. 2015;7(24):13174–9. https://doi.org/10.1021/am505592e.CrossRefPubMed

101.

Jiang D, Sun Y, Li J, Li Q, Lv M, Zhu B, et al. Multiple-armed tetrahedral DNA nanostructures for tumor-targeting, dual-modality in vivo imaging. ACS Appl Mater Interfaces. 2016;8(7):4378–84. https://doi.org/10.1021/acsami.5b10792.CrossRefPubMed

102.

Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991;88(17):7595–9. https://doi.org/10.1073/pnas.88.17.7595.CrossRefPubMedPubMedCentral

103.

Wang H, Liu Q, Lan X, Jiang D. Framework nucleic acids in nuclear medicine imaging: shedding light on nano-bio interactions. Angew Chem Int Ed Engl. 2021. https://doi.org/10.1002/anie.202111980.CrossRefPubMedPubMedCentral

104.

Jiang D, Im HJ, Boleyn ME, England CG, Ni D, Kang L, et al. Efficient renal clearance of DNA tetrahedron nanoparticles enables quantitative evaluation of kidney function. Nano Res. 2019;12(3):637–42. https://doi.org/10.1007/s12274-019-2271-5.CrossRefPubMed

105.

Jiang D, Ge Z, Im HJ, England CG, Ni D, Hou J, et al. DNA origami nanostructures can exhibit preferential renal uptake and alleviate acute kidney injury. Nat Biomed Eng. 2018;2(11):865–77. https://doi.org/10.1038/s41551-018-0317-8.CrossRefPubMedPubMedCentral

106.

Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, et al. Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of (177)Lu-DOTA-EB-TATE. J Nucl Med. 2021;62(3):386–92. https://doi.org/10.2967/jnumed.120.248658.CrossRefPubMedPubMedCentral

107.

Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, et al. (177)Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2020;61(12):1772–8. https://doi.org/10.2967/jnumed.120.242263.CrossRefPubMed

108.

Nutiu R, Li Y. Structure-switching signaling aptamers. J Am Chem Soc. 2003;125(16):4771–8. https://doi.org/10.1021/ja028962o.CrossRefPubMed

109.

Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181–202. https://doi.org/10.1038/nrd.2016.199.CrossRefPubMed

110.

Burdick AD, Sciabola S, Mantena SR, Hollingshead BD, Stanton R, Warneke JA, et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid–modified antisense oligonucleotides. Nucleic Acids Res. 2014;42(8):4882–91. https://doi.org/10.1093/nar/gku142.CrossRefPubMedPubMedCentral

111.

Shen W, De Hoyos CL, Sun H, Vickers TA, Liang XH, Crooke ST. Acute hepatotoxicity of 2’ fluoro-modified 5–10-5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Res. 2018;46(5):2204–17. https://doi.org/10.1093/nar/gky060.CrossRefPubMedPubMedCentral

112.

Lincoff AM, Mehran R, Povsic TJ, Zelenkofske SL, Huang Z, Armstrong PW, et al. Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. Lancet. 2016;387(10016):349–56. https://doi.org/10.1016/s0140-6736(15)00515-2.CrossRefPubMed

113.

Ivens IA, Achanzar W, Baumann A, Brandli-Baiocco A, Cavagnaro J, Dempster M, et al. PEGylated biopharmaceuticals: current experience and considerations for nonclinical development. Toxicol Pathol. 2015;43(7):959–83. https://doi.org/10.1177/0192623315591171.CrossRefPubMed

114.

Karabasz A, Szczepanowicz K, Cierniak A, Mezyk-Kopec R, Dyduch G, Szczęch M, et al. In vivo studies on pharmacokinetics, toxicity and immunogenicity of polyelectrolyte nanocapsules functionalized with two different polymers: poly-L-glutamic acid or PEG. Int J Nanomedicine. 2019;14:9587–602. https://doi.org/10.2147/ijn.S230865.CrossRefPubMedPubMedCentral

115.

Ni S, Zhuo Z, Pan Y, Yu Y, Li F, Liu J, et al. Recent progress in aptamer discoveries and modifications for therapeutic applications. ACS Appl Mater Interfaces. 2021;13(8):9500–19. https://doi.org/10.1021/acsami.0c05750.CrossRefPubMed

116.

Caruthers MH. Gene synthesis machines: DNA chemistry and its uses. Science. 1985;230(4723):281–5. https://doi.org/10.1126/science.3863253.CrossRefPubMed

Title: Advances in aptamer-based nuclear imaging
Authors: Wenyu Song
Yangmeihui Song
Qian Li
Chunhai Fan
Xiaoli Lan
Dawei Jiang
Publication date: 08-04-2022
Publisher: Springer Berlin Heidelberg
Keyword: Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05782-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Advances in aptamer-based nuclear imaging

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2022

Preclinical and exploratory human studies of novel 68Ga-labeled D-peptide antagonist for PET imaging of TIGIT expression in cancers

Recent advances in aggregation-induced emission luminogens in photoacoustic imaging

Higher accuracy of [68 Ga]Ga-DOTA-FAPI-04 PET/CT comparing with 2-[18F]FDG PET/CT in clinical staging of NSCLC

State-of-the-art of nuclear medicine and molecular imaging in China: after the first 66 years (1956–2022)

18F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with 18F-FDG

Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study